The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
Open accessAbstract
There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression to severe coronavirus disease 2019 (COVID-19). In a phase 2a double-blind, placebo-controlled, randomized, multicenter clinical trial, we evaluated the safety, tolerability, and antiviral efficacy of the nucleoside analog molnupiravir in 202 unvaccinated participants with confirmed SARS-CoV-2 infection and symptom duration <7 days. Participants were randomized 1:1 to receive molnupiravir (200 mg) or placebo and then 3:1 to receive molnupiravir (400 or 800 mg) or placebo, orally twice daily for 5 days. Antiviral activity was assessed by reverse transcriptase polymerase chain reaction (RT-PCR) for SARS-CoV-2 RNA in nasopharyngeal swabs. Infectious virus was assessed by inoculation of cultured Vero cells with samples from nasopharyngeal swabs and was detected by RT-PCR. Time to viral RNA clearance (primary endpoint) was decreased in the 800-mg molnupiravir group (median 14 days) compared to the placebo group (median 15 days) (log rank P value = 0.013). Of participants receiving 800 mg of molnupiravir, 92.5% achieved viral RNA clearance compared with 80.3% of placebo recipients by study end (4 weeks). Infectious virus (secondary endpoint) was detected in swabs from 1.9% of the 800-mg molnupiravir group compared with 16.7% of the placebo group at day 3 of treatment ( P = 0.016). At day 5 of treatment, infectious virus was not isolated from any participants receiving 400 or 800 mg of molnupiravir compared with 11.1% of placebo recipients ( P = 0.034 and 0.027, respectively). Molnupiravir was well tolerated across all doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., Martín-Quirós, A., Caraco, Y., Williams-Diaz, A., Brown, M. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116044 · Cited by 1,857
Viral dynamics in mild and severe cases of COVID-19
Liu, Y., Yan, L.-M., Wan, L., Xiang, T.-X., Le, A., Liu, J.-M., Peiris, M., Poon, L. L. M., & Zhang, W. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30232-2 · Cited by 1,727
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B. J., Soo, Y., Rofail, D., Im, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035002 · Cited by 1,642
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282
Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples
Bullard, J., Dust, K., Funk, D., Strong, J. E., Alexander, D., Garnett, L., Boodman, C., Bello, A., Hedley, A., Schiffman, Z., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa638 · Cited by 1,075
Sheahan, T. P., Sims, A. C., Zhou, S., Graham, R. L., Pruijssers, A. J., Agostini, M. L., Leist, S. R., Schäfer, A., Dinnon, K. H., Stevens, L. J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb5883 · Cited by 1,071
Self-citationA SARS-like cluster of circulating bat coronaviruses shows potential for human emergence
Menachery, V. D., Yount, B. L., Debbink, K., Agnihothram, S., Gralinski, L. E., Plante, J. A., Graham, R. L., Scobey, T., Ge, X.-Y., Donaldson, E. F., et al. (2015) · Nature Medicine · doi:10.1038/nm.3985 · Cited by 901
Self-citationGottlieb, R. L., Nirula, A., Chen, P., Boscia, J., Heller, B., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · JAMA · doi:10.1001/jama.2021.0202 · Cited by 872
Premkumar, L., Segovia-Chumbez, B., Jadi, R., Martinez, D. R., Raut, R., Markmann, A. J., Cornaby, C., Bartelt, L., Weiss, S., Park, Y., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc8413 · Cited by 868
Self-citationSinganayagam, A., Patel, M., Charlett, A., Lopez Bernal, J., Saliba, V., Ellis, J., Ladhani, S., Zambon, M., & Gopal, R. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.32.2001483 · Cited by 846
van Kampen, J. J. A., van de Vijver, D. A. M. C., Fraaij, P. L. A., Haagmans, B. L., Lamers, M. M., Okba, N., van den Akker, J. P. C., Endeman, H., Gommers, D. A. M. P. J., Cornelissen, J. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20568-4 · Cited by 838
Clinical progression of patients with COVID-19 in Shanghai, China
Chen, J., Qi, T., Liu, L., Ling, Y., Qian, Z., Li, T., Li, F., Xu, Q., Zhang, Y., Xu, S., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.004 · Cited by 789
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
Kabinger, F., Stiller, C., Schmitzová, J., Dienemann, C., Kokic, G., Hillen, H. S., Höbartner, C., & Cramer, P. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00651-0 · Cited by 750
Antibody evasion by the P.1 strain of SARS-CoV-2
Dejnirattisai, W., Zhou, D., Supasa, P., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Tuekprakhon, A., Nutalai, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.055 · Cited by 583
Pruijssers, A. J., George, A. S., Schäfer, A., Leist, S. R., Gralinksi, L. E., Dinnon, K. H., Yount, B. L., Agostini, M. L., Stevens, L. J., Chappell, J. D., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107940 · Cited by 510
Self-citationShedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer
Aydillo, T., Gonzalez-Reiche, A. S., Aslam, S., van de Guchte, A., Khan, Z., Obla, A., Dutta, J., van Bakel, H., Aberg, J., García-Sastre, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2031670 · Cited by 415
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
Wahl, A., Gralinski, L. E., Johnson, C. E., Yao, W., Kovarova, M., Dinnon, K. H., Liu, H., Madden, V. J., Krzystek, H. M., De, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03312-w · Cited by 409
Self-citationPainter, W. P., Holman, W., Bush, J. A., Almazedi, F., Malik, H., Eraut, N. C. J. E., Morin, M. J., Szewczyk, L. J., & Painter, G. R. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02428-20 · Cited by 397
Self-citationCox, R. M., Wolf, J. D., & Plemper, R. K. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00835-2 · Cited by 387
Agostini, M. L., Pruijssers, A. J., Chappell, J. D., Gribble, J., Lu, X., Andres, E. L., Bluemling, G. R., Lockwood, M. A., Sheahan, T. P., Sims, A. C., et al. (2019) · Journal of Virology · doi:10.1128/jvi.01348-19 · Cited by 337
Self-citationMolnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
Gordon, C. J., Tchesnokov, E. P., Schinazi, R. F., & Götte, M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100770 · Cited by 293
Abdelnabi, R., Foo, C. S.-Y., Jonghe, S. D., Maes, P., Weynand, B., & Neyts, J. H. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab361 · Cited by 133
Author Correction: Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2984-3 · Cited by 109
Painter, G. R., Bowen, R. A., Bluemling, G. R., DeBergh, J., Edpuganti, V., Gruddanti, P. R., Guthrie, D. B., Hager, M. W., Kuiper, D. L., Lockwood, M. A., et al. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.104597 · Cited by 103
Folgueira, M. D., Luczkowiak, J., Lasala, F., Pérez‐Rivilla, A., & Delgado, R. B. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.02.014 · Cited by 90
Markmann, A. J., Giallourou, N., Bhowmik, D. R., Hou, Y. J., Lerner, A., Martinez, D. R., Premkumar, L., Root, H. B., van Duin, D., Napravnik, S., et al. (2021) · mSphere · doi:10.1128/msphere.00275-21 · Cited by 56
Self-citationSeroepidemiology of SARS-CoV-2 infections in an urban population-based cohort in León, Nicaragua
González, F., Vielot, N. A., Sciaudone, M., Toval-Ruíz, C., Premkumar, L., Gutiérrez, L., Centeno, E., Munguia, N., Blandón, P., de Silva, A. M., et al. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821002144 · Cited by 15
Cited by
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., Martín-Quirós, A., Caraco, Y., Williams-Diaz, A., Brown, M. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116044 · Cited by 1,857
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
Killingley, B., Mann, A. J., Kalinova, M., Boyers, A., Goonawardane, N., Zhou, J., Lindsell, K., Hare, S. S., Brown, J., Frise, R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01780-9 · Cited by 530
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Iketani, S., Mohri, H., Culbertson, B., Hong, S. J., Duan, Y., Luck, M. I., Annavajhala, M. K., Guo, Y., Sheng, Z., Uhlemann, A.-C., et al. (2023) · Nature · doi:10.1038/s41586-022-05514-2 · Cited by 480
Vangeel, L., Chiu, W., De Jonghe, S., Maes, P., Slechten, B., Raymenants, J., André, E., Leyssen, P., Neyts, J., & Jochmans, D. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105252 · Cited by 433
Wen, W., Chen, C., Tang, J., Wang, C., Zhou, M., Cheng, Y., Zhou, X., Wu, Q., Zhang, X., Feng, Z., et al. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2034936 · Cited by 423
Metadata
- Authors
- Fischer, W. A., Eron, J. J., Holman, W., Cohen, M. S., Fang, L., Szewczyk, L. J., Sheahan, T. P., Baric, R., Mollan, K. R., Wolfe, C. R., Duke, E. R., Azizad, M. M., Borroto-Esoda, K., Wohl, D. A., Coombs, R. W., James Loftis, A., Alabanza, P., Lipansky, F., & Painter, W. P.
- Venue
- Science Translational Medicine
- Published
- 2022-01-19
- Volume
- 14
- Issue
- 628
- Pages
- eabl7430-eabl7430
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W4200560336
- Cited by
- 529
- References
- 27
- FWCI
- 35.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.